News | March 18, 2026
Zydus, Lupin join forces to expand access to semaglutide in India
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect
The company announced positive topline data from the Phase 3 ADorable-1 trial
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
Giredestrant shows promise despite missing primary goal
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
Subscribe To Our Newsletter & Stay Updated
